C-myc、nm23-H1基因在宫颈癌中表达的意义及相互关系  

A STUDY ON C-myc,nm23-H1 EXPRESSION IN CERVICAL CARCINOMA AND CLINICAL SIGNIFICANCE

作　　者：苏玲娣[1] 刘曼华[1] 程英[1] 季小华[1] 陶潜[1] 

机构地区：[1]南通医学院第二附属医院妇产科,南通226001

出　　处：《南通医学院学报》2002年第3期262-263,265,共3页ACTA Academiae Medicinae Nantong

摘　　要：目的 :探讨 C- myc、nm2 3- H1两种基因在宫颈癌中表达及其临床意义。方法 :应用免疫组化法检测宫颈癌 4 0例、宫颈上皮内瘤形成 (CIN) 10例及正常宫颈 2 0例组织标本中 C- myc和 nm2 3- H1蛋白表达 ,采用统计学χ2 检验方法 ,分析这 2种蛋白表达与临床病理及预后关系。结果 :(1) C- myc蛋白表达率 :宫颈癌组织为 4 0 .0 0 % ,正常宫颈组织为 10 .0 0 % ,CIN为 2 0 .0 0 % ,表达与病理分类有关 ,腺癌表达率高于鳞癌 ,但差异无显著性 (P>0 .0 5 ) ;过表达与临床分期及病理学分级相关 (P<0 .0 5 ) ;(2 )宫颈癌 nm 2 3- H1蛋白表达率为 4 0 .0 0 % ,宫颈炎组织表达率为5 .0 0 % ,不典型增生组织未见阳性表达 ,差异有极显著性 (P<0 .0 1) ,腺癌表达率为 83.33%高于鳞癌 32 .35 % ,差异有显著性 (P<0 .0 5 ) ;(3) 2种基因蛋白表达的比较 :C- myc、nm2 3- H12种基因在宫颈癌中表达差异无显著性 (P>0 .0 5 )。结论 :C- m yc表达与宫颈癌发生发展有一定关系 ;nm2 3- H1表达在宫颈腺癌早期呈高表达 ,可能为机体抑制肿瘤转移的防御性反应。Objective: To investigate the expression of C-myc and nm23-H1 in cervical carcinoma and clinical significance. Method: Expression of C-myc and nm23-H1 proteins was examined immunohistochemically in 40 cases of carcinoma of the uterine cervix and 10 cases of CIN and 20 cases of cervical epithelium. The relationship between their expression with clinicpathologic factors and prognosis was analyzed by chi-square test. Results: The expression rate of C-myc was 40.00% in cervical carcinoma and 20.00% in CIN and 10.00% in cervical epithelium(P<0.05). The expression was in connection with histological grade and clinic types(P<0.05). (2)The expression rate of nm23-H1was 40.00% in cervical carcinoma;5.00% in cervical epithelium and none in CIN (P<0.01) . and was in connection with pathlological types: the expression rate of adenocarcinoma was 83.33% and squamous cell carcinoma was 32.35%(P<0.05). 2.There was no relationship between expression of C-myc and nm23-H1 (P>0.05). Conclusions: Expression of C-myc was related to progression of Cervical Carcinoma; Higher expression of nm23-H1 may occur in early development stage of adenocarcinoma. It was possible that organism resisted tumor's metastasis. [

关 键 词：宫颈癌 C-MYC NM23-H1 基因表达 临床意义 免疫组化法 预后 

分 类 号：R737.33[医药卫生—肿瘤]